Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.

Aditi Kharat,Richard E. Nelson,Trang H. Au,Joseph Biskupiak

Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.

2021

Aditi Kharat
Richard E. Nelson
Trang H. Au
Joseph Biskupiak

BACKGROUND: Pancreatic cancer is associated with low median overall survival. Combination chemotherapy regimens FOLFIRINOX and gemcitabine with nab-paclitaxel (GemNab) are the new adjuvant treatmen...

Keywords:

Nab-paclitaxel
combination chemotherapy
Cost-effectiveness analysis
overall survival
Pancreatic cancer
FOLFIRINOX
Oncology
Adjuvant
Internal medicine
Medicine
Gemcitabine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations